Strategic Focus Harvard-believed regenerative medicine startup targeting neuroprotection for retinal degeneration, with a beachhead in Retinitis Pigmentosa and plans to expand to Dry-AMD and Glaucoma—take incentive to propose collaborations on neuroprotective platforms and early validation studies.

Size & Agility Small team (2-10 employees) suggests high agility and potential for fast decision cycles; ideal partner for pilot programs, fast-track partnerships, and co-development agreements with clear scopes and lightweight governance.

Funding Signals Revenue range of 1–10 million indicates growing biotech activity with budget for external collaborations, contract research, and milestone-based partnerships; approach with value-focused proposals and risk-sharing models.

Tech & Compliance Cloud-based infrastructure (AWS, Cloudflare, Webflow, Microsoft 365) and privacy-conscious web presence imply readiness for scalable digital collaboration, secure data handling, and potential cloud-based R&D tooling or vendor integration opportunities.

Competitive Landscape Operates in a biotech niche with peers of large scale (Allergan, Genentech, Novartis) but significantly smaller competitors like Adverum Biotechnologies; position as a nimble partner for early-stage trials, translational research, and niche retinal disease programs.